Skip to main content
. Author manuscript; available in PMC: 2014 Jul 3.
Published in final edited form as: Bone Marrow Transplant. 2010 Jun 28;46(4):510–515. doi: 10.1038/bmt.2010.160

Table 3.

Outcomes for topotecan, melphalan and CY regimen

Outcome Median (range)
Plt >20 × 109/L post transplant 9 (6–79)
ANC >0.5 × 109/L post transplant 10 (7–11)
Mortality 24 (40)
 First remission 16/41 (39) P 0.51
 Relapse-refractory 8/19 (42)
Progression 40 (67)
 First remission 29/41 (70) P 0.384
 Relapse-refractory 8/19 (57)
4-year OS 66%
4-year PFS 30%